A Metalloporphyrin Antioxidant Alters Cytokine Responses after Irradiation in a Prostate Tumor Model
Authors:
- Asma RizviARAsma Rizvi
- James D. CrapoJCJames D. Crapo
- Robert D. PearlsteinRPRobert D. Pearlstein
- James M. SlaterJSJames M. Slater
- Daila S. GridleyDGDaila S. Gridley
- 1 April 2010
- journal article
- Published by Radiation Research Society in Radiation Research
- Vol. 173 (4) , 441-452
Abstract
The goal of this study was to evaluate cytokine secretion capacity in a mouse model of prostate cancer, both with and without metalloporphyrin antioxidant and radiation treatment. C57BL/6 mice with subcutaneous RM-9 tumors were treated daily for 12 days with MnTE-2-PyP(5+) [Mn (III) tetrakis (N-ethylpyridinium-2-yl) porphyrin], beginning 1 day after injection of RM-9 cells; a 10-Gy tumor-localized dose of (60)Co gamma rays was administered in a single fraction on day 7. Spleen, tumors and plasma were collected on day 12. T cells in the spleen were activated with anti-CD3 antibody and supernatants were collected. Twenty-two cytokines were quantified in spleen supernatants, five in tumor homogenates, and three in plasma using multiplex bead array technology and ELISA. The presence of a tumor had significant effects on many of the cytokines quantified (P < 0.05). Tumor-induced depression was evident for eight spleen cytokines (TNF-alpha, G-CSF, GM-CSF, IFN-gamma, IL10, IP-10, MIP-1alpha and mKC), whereas only three were enhanced (IL1beta, IL6 and MCP-1). Radiotherapy resulted in enhanced splenocyte capacity to produce IL4 and IL13 and increased IL4, MCP-1 and VEGF in tumors (P < 0.05). Addition of MnTE-2-PyP(5+) to radiation decreased the concentrations of IL4, IL13 and TGF-beta1 in spleen supernatants and IL4 and VEGF in tumors (P < 0.05 compared to radiation alone). Some differences were also noted in plasma cytokines. Overall, the findings suggest that administration of MnTE-2-PyP(5+) together with radiotherapy may enhance anti-tumor immune responsiveness and decrease the risk for radiation-induced normal tissue toxicities.Keywords
This publication has 57 references indexed in Scilit:
- Inhibition of Transforming Growth Factor-β–Mediated Immunosuppression in Tumor-Draining Lymph Nodes Augments Antitumor Responses by Various Immunologic Cell TypesCancer Research, 2009
- Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor CellsThe Journal of Immunology, 2009
- Pathways connecting inflammation and cancerCurrent Opinion in Genetics & Development, 2008
- Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4Cell Death & Differentiation, 2008
- ‘Yin–Yang’ functions of transforming growth factor‐β and T regulatory cells in immune regulationImmunological Reviews, 2007
- Regulatory T Cells, Transforming Growth Factor–β, and Immune SuppressionProceedings of the American Thoracic Society, 2007
- Sod mimetics are coming of ageNature Reviews Drug Discovery, 2002
- IL-13 induces eosinophil recruitment into the lung by an IL-5– and eotaxin-dependent mechanismJournal of Allergy and Clinical Immunology, 2001
- Patterns of care studies: Past, present, and futureSeminars in Radiation Oncology, 1997
- Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cellsImmunology Today, 1994